AC Immune Expands Advisory Leadership With Appointment Of Dr. Catherine Mummery As Chair Of The Clinical Advisory Board To Drive Clinical Development Expertise

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, has announced the appointment of Professor Catherine Mummery as Chairwoman of its Clinical Advisory Board (CAB). Prof. Mummery is a distinguished neurologist and an expert in dementia clinical trials, bringing a wealth of experience to AC Immune’s leadership team. Prof. Mummery currently leads the cognitive disorders service at the UK’s National Hospital for Neurology and Neurosurgery (NHNN), where she has served as a consultant neurologist since 2004. 

She also heads the novel therapeutics program at the Dementia Research Centre, University College London (UCL), and serves as the deputy director of the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit focused on early-stage clinical trials in neurodegenerative diseases. Throughout her career, Prof. Mummery has served as a senior investigator on over 20 early-stage studies evaluating disease-modifying therapies for various dementias. Her extensive research includes leading the first-ever clinical trial of a gene-silencing therapy targeting Tau in Alzheimer’s disease, as well as contributing to trials involving AC Immune’s anti-pTau active immunotherapy candidate ACI-35.030 (JNJ-2056).

Dr. Andrea Pfeifer, CEO of AC Immune SA, expressed her enthusiasm about the appointment, stating that Prof. Mummery’s leadership marks an important milestone for the company. Dr. Pfeifer noted that Prof. Mummery’s role in the recently published Phase 1b/2a trial of ACI-35.030 has been instrumental in advancing AC Immune’s SupraAntigen® immunotherapies. She added that this new position will expand Prof. Mummery’s influence across the company’s broader pipeline, including three Phase 2 active immunotherapies and several novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases, such as ACI-19764 (targeting NLRP3), the Morphomer® Tau program, and the Morphomer® α-syn program.

Commenting on her appointment, Prof. Mummery said she is honored to lead AC Immune’s Clinical Advisory Board and looks forward to guiding the company’s efforts in precision prevention for neurodegenerative diseases. She emphasized her excitement about the company’s advancing clinical programs, particularly the active immunotherapies nearing key inflection points and the first-in-class small molecules designed to target intracellular pathologic proteins.

The Clinical Advisory Board at AC Immune provides strategic direction on clinical development and regulatory pathways. Members are chosen for their scientific expertise and contributions to the field of neurodegeneration. Alongside Prof. Mummery, the CAB includes several internationally recognized experts: Dr. Reisa Sperling from Brigham and Women's Hospital and Massachusetts General Hospital (USA); Dr. Murat Emre from Istanbul University (Turkey); Dr. Lon Schneider from the Keck School of Medicine, University of Southern California (USA); Dr. Pierre Tariot from the Banner Alzheimer’s Institute (USA); and Dr. Juan Fortea from Hospital of Sant Pau (Spain). AC Immune also expressed gratitude to Dr. Kaj Blennow, the outgoing Chair of the CAB, for his invaluable contributions and guidance during his tenure.